SCHEMBL21292902

SCHEMBL21292902

O=S(=O)(NC1CCC1)c1ccc(CO)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.68
KDM4E B2RXH2 1/20 0.68
RECQL P46063 1/20 0.68
ALDH1A1 P00352 7/20 0.57
CYP3A4 P08684 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
HTT P42858 1/20 0.57
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 4/20 0.53
HPGD P15428 1/20 0.53
GAA P10253 2/20 0.52
POLB P06746 1/20 0.52
KCNH2 Q12809 2/20 0.51
HRH3 Q9Y5N1 2/20 0.51
NAMPT P43490 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12189303 0.83 SMN1; SMN2 (0.68) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL5464162 0.83 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL14052269 0.81 KDM4E (0.64) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL12189228 0.80 SMN1; SMN2 (0.73) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL9302583 0.79 SMN1; SMN2 (0.71) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL20946378 0.79 SMN1; SMN2 (0.71) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL12188930 0.79 SMN1; SMN2 (0.71) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL3013547 0.77 MAPK1 (0.90) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL13297951 0.77 ALDH1A1 (0.90) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4
SCHEMBL4024058 0.77 SMN1; SMN2 (0.75) SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759075-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
EP-3759075-A1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE Ferro Therapeutics, Inc. (US) 2021-01-06 EP disclosed
CN-112041301-A Compounds having iron death inducing activity and methods of use thereof 费罗治疗公司 2020-12-04 CN disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 SMN1; SMN2 2416/4885KDM4E 2312/4885RECQL 2822/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 SMN1; SMN2 2428/4885KDM4E 2426/4885RECQL 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.